Bioniche Life Scienc (BNHLF) 0.2134 $BNHLF
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Fri Aug 22, 1:12PM CDT
Trading resumes in:
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Aug 21, 2:29PM CDT
The following issues have been halted by IIROC:
Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States
PR Newswire - Tue Aug 19, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that it is targeting Q1/2015 for the filing of a Biologics License Application (BLA) with the United States Food and Drug Administration (FDA) for Bioniche's lead program Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guérin (BCG) therapy. This projected timeline integrates the conclusions of a regulatory gap analysis prepared by its consultants (reviewing the state of each BLA module and estimating the time to complete) with the planning and scheduling of a pre-BLA meeting between Bioniche and the FDA prior to the BLA filing.
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States
PR Newswire - Tue Jul 29, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, an application for Orphan Drug Designation for its Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory/relapsing high grade non-muscle invasive bladder cancer.
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States
PR Newswire - Fri Jul 18, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today provided a key regulatory update on its flagship Phase 3 program, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory high grade non-muscle invasive bladder cancer.
Global Animal Growth Promoters and Performance Enhancers Market Report 2014-2018
M2 - Fri Jul 11, 2:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4drwgt/animal_growth) has announced the addition of the "Global Animal Growth Promoters and Performance Enhancers Market Report 2014-2018" report to their offering. Antibiotics was the largest segment of the animal growth promoters market and was valued at $4,489.7 million in 2013 However, feed enzymes are expected to grow at the fastest rate owing to the increasing popularity and demand for alternatives to antibiotic and hormonal growth promoters. The animal growth promoters and performance enhancers market is segmented into antibiotics/antimicrobials, probiotics and prebiotics, organic acids, feed enzymes, hormonal growth promonants, ?-agonists, phytogenics, and others. These growth promoters are used in the animal feed to increase their growth and to enhance their performance. The animal growth promoters and performance enhancers market, by animal industry is segmented into porcine, poultry, livestock, equine, and aquaculture. The porcine industry made use of the largest amount of growth promoters, in 2013, followed by poultry and livestock. The changing consumption trend globally is likely to increase the demand for pork meat, thus making more use of the growth promoters. Countries such as Brazil, Australia, and New Zealand in the RoW region are also expected to witness growth in this market, owing to very little regulations on the use of growth promoters in animals and the increasing meat demand. The global animal growth promoters and performance enhancers market witness's high competitive intensity as there are many big and small firms with similar product offerings. These companies adopt various strategies to increase their market share and to establish a strong foothold in the global market. However, increasing awareness amongst consumers regarding the hazards of using antibiotic growth promoters and their ban are likely to hamper the growth of this market. The report extensively covers the animal growth promoters and performance enhancers market (products and animals). Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Animal Performance Enhancers Market, By Product 5 Global Animal Performance Enhancers Market, By Animal 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles - Bayer Animal Health (A Subsidiary of Bayer Ag) - Biomin Holding Gmbh - Bioniche Animal Health (A Division of Bioniche Life Sciences, Inc.) - Boehringer Ingelheim - Bupo Animal Health (PTY) - Cargill, Inc. - Elanco Animal Health (A Division of Eli Lilly and Company) - Merck Animal Health (A Subsidiary of Merck & Co., Inc.) - Royal Dsm N.V. - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4d...mal_growth
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014
M2 - Mon Jun 16, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n696j4/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects Companies Mentioned: - Bioniche Life Sciences - TARIS BioMedical - Spectrum Pharmaceuticals. - Altor BioScience - Telormedix - Heat Biologics - Viventia Biotechnologies - Cold Genesys - Laurantis Pharma For more information visit http://www.researchandmarkets.com/research/n696j4/non_muscle
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Fri Jun 13, 8:06AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) - ("Bioniche" or the "Company"
, a clinical stage biotechnology company whose anchor product is a Phase III treatment for non-muscle-invasive bladder cancer, today announced that Dr. Michael Berendt, Chief Executive Officer and Chief Scientist of Bioniche Life Sciences Inc., will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18, 2014 at 3:30 P.M. EDT in Toronto. Bioniche's corporate presentation will be available on the Company's website at www.bioniche.com following the presentation.
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast
PR Newswire - Thu Mar 13, 5:06PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today held a conference call and audio webcast for its shareholders, at which time, Company representatives provided several corporate updates. The corporate presentation used during today's call/webcast is available on the Company's website (www.Bioniche.com) under Investors - Corporate Presentations.
Bioniche Life Sciences Inc. Announces Key Corporate Updates
PR Newswire - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
PR Newswire - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer
PR Newswire - Tue Jan 07, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage biotechnology company, today announced the appointment of Donald Olds as Chief Operating Officer, effective immediately.
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement
PR Newswire - Wed Sep 11, 1:13PM CDT
new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders -
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Fri Aug 22, 1:12PM CDT
Trading resumes in:
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Aug 21, 2:29PM CDT
The following issues have been halted by IIROC:
Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States
PR Newswire - Tue Aug 19, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced that it is targeting Q1/2015 for the filing of a Biologics License Application (BLA) with the United States Food and Drug Administration (FDA) for Bioniche's lead program Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guérin (BCG) therapy. This projected timeline integrates the conclusions of a regulatory gap analysis prepared by its consultants (reviewing the state of each BLA module and estimating the time to complete) with the planning and scheduling of a pre-BLA meeting between Bioniche and the FDA prior to the BLA filing.
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States
PR Newswire - Tue Jul 29, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, an application for Orphan Drug Designation for its Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory/relapsing high grade non-muscle invasive bladder cancer.
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States
PR Newswire - Fri Jul 18, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today provided a key regulatory update on its flagship Phase 3 program, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory high grade non-muscle invasive bladder cancer.
Global Animal Growth Promoters and Performance Enhancers Market Report 2014-2018
M2 - Fri Jul 11, 2:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4drwgt/animal_growth) has announced the addition of the "Global Animal Growth Promoters and Performance Enhancers Market Report 2014-2018" report to their offering. Antibiotics was the largest segment of the animal growth promoters market and was valued at $4,489.7 million in 2013 However, feed enzymes are expected to grow at the fastest rate owing to the increasing popularity and demand for alternatives to antibiotic and hormonal growth promoters. The animal growth promoters and performance enhancers market is segmented into antibiotics/antimicrobials, probiotics and prebiotics, organic acids, feed enzymes, hormonal growth promonants, ?-agonists, phytogenics, and others. These growth promoters are used in the animal feed to increase their growth and to enhance their performance. The animal growth promoters and performance enhancers market, by animal industry is segmented into porcine, poultry, livestock, equine, and aquaculture. The porcine industry made use of the largest amount of growth promoters, in 2013, followed by poultry and livestock. The changing consumption trend globally is likely to increase the demand for pork meat, thus making more use of the growth promoters. Countries such as Brazil, Australia, and New Zealand in the RoW region are also expected to witness growth in this market, owing to very little regulations on the use of growth promoters in animals and the increasing meat demand. The global animal growth promoters and performance enhancers market witness's high competitive intensity as there are many big and small firms with similar product offerings. These companies adopt various strategies to increase their market share and to establish a strong foothold in the global market. However, increasing awareness amongst consumers regarding the hazards of using antibiotic growth promoters and their ban are likely to hamper the growth of this market. The report extensively covers the animal growth promoters and performance enhancers market (products and animals). Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Animal Performance Enhancers Market, By Product 5 Global Animal Performance Enhancers Market, By Animal 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles - Bayer Animal Health (A Subsidiary of Bayer Ag) - Biomin Holding Gmbh - Bioniche Animal Health (A Division of Bioniche Life Sciences, Inc.) - Boehringer Ingelheim - Bupo Animal Health (PTY) - Cargill, Inc. - Elanco Animal Health (A Division of Eli Lilly and Company) - Merck Animal Health (A Subsidiary of Merck & Co., Inc.) - Royal Dsm N.V. - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4d...mal_growth
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014
M2 - Mon Jun 16, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n696j4/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects Companies Mentioned: - Bioniche Life Sciences - TARIS BioMedical - Spectrum Pharmaceuticals. - Altor BioScience - Telormedix - Heat Biologics - Viventia Biotechnologies - Cold Genesys - Laurantis Pharma For more information visit http://www.researchandmarkets.com/research/n696j4/non_muscle
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Fri Jun 13, 8:06AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) - ("Bioniche" or the "Company"
, a clinical stage biotechnology company whose anchor product is a Phase III treatment for non-muscle-invasive bladder cancer, today announced that Dr. Michael Berendt, Chief Executive Officer and Chief Scientist of Bioniche Life Sciences Inc., will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18, 2014 at 3:30 P.M. EDT in Toronto. Bioniche's corporate presentation will be available on the Company's website at www.bioniche.com following the presentation. Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast
PR Newswire - Thu Mar 13, 5:06PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today held a conference call and audio webcast for its shareholders, at which time, Company representatives provided several corporate updates. The corporate presentation used during today's call/webcast is available on the Company's website (www.Bioniche.com) under Investors - Corporate Presentations.
Bioniche Life Sciences Inc. Announces Key Corporate Updates
PR Newswire - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
PR Newswire - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer
PR Newswire - Tue Jan 07, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage biotechnology company, today announced the appointment of Donald Olds as Chief Operating Officer, effective immediately.
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement
PR Newswire - Wed Sep 11, 1:13PM CDT
new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders -
